Assembly Biosciences Inc ASMB
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2010-12-17 |
| Shares Out. | 19,820,000 |
| Website | assemblybio.com/ ↗ |
| Phone | 18009279800 |
| Employees | 73 |
| Revenue | $8.2M |
| Gross Profit | $8.2M |
| Net Income | -$9.1M |
| Free Cash Flow | -$39.8M |
| Total Assets | $235.5M |
| Total Liabilities | $36.9M |
| Equity | $198.6M |
About Assembly Biosciences Inc
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
Assembly Biosciences Inc is a publicly traded company under the ticker symbol ASMB on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
10 analysts (2026-07-01)